Bio-Techne (NASDAQ:TECH) Stock Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Bio-Techne Co. (NASDAQ:TECH). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Bio-Techne Trading Down 2.0 %

NASDAQ:TECH opened at $58.73 on Friday. Bio-Techne Co. has a 52 week low of $56.60 and a 52 week high of $85.57. The firm’s fifty day moving average is $66.56 and its 200-day moving average is $71.45. The firm has a market cap of $9.28 billion, a P/E ratio of 59.32, a P/E/G ratio of 2.88 and a beta of 1.30. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.77 and a current ratio of 3.94.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. Equities analysts expect that Bio-Techne Co. will post 1.67 earnings per share for the current year.

Bio-Techne Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Monday, February 17th were given a $0.08 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.54%. Bio-Techne’s dividend payout ratio (DPR) is currently 32.32%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TECH. Scotiabank lifted their target price on Bio-Techne from $88.00 to $90.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 6th. Royal Bank of Canada boosted their target price on shares of Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a research report on Thursday, February 6th. Baird R W cut shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. StockNews.com downgraded shares of Bio-Techne from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Robert W. Baird cut shares of Bio-Techne from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $88.00 to $68.00 in a research report on Wednesday, February 19th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Bio-Techne presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.25.

Institutional Investors Weigh In On Bio-Techne

A number of institutional investors and hedge funds have recently made changes to their positions in TECH. UMB Bank n.a. raised its stake in shares of Bio-Techne by 46.4% in the fourth quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 168 shares during the last quarter. Brooklyn Investment Group purchased a new stake in Bio-Techne during the third quarter worth about $39,000. Itau Unibanco Holding S.A. bought a new stake in Bio-Techne in the fourth quarter worth about $41,000. Quest Partners LLC purchased a new stake in shares of Bio-Techne during the 3rd quarter worth approximately $43,000. Finally, GeoWealth Management LLC bought a new stake in shares of Bio-Techne in the 4th quarter worth approximately $43,000. Institutional investors and hedge funds own 98.95% of the company’s stock.

Insider Buying and Selling at Bio-Techne

In related news, Director Amy E. Herr sold 1,860 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the transaction, the director now directly owns 1,976 shares of the company’s stock, valued at approximately $130,336.96. This trade represents a 48.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kim Kelderman sold 13,392 shares of the business’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the sale, the chief executive officer now directly owns 39,004 shares in the company, valued at $3,014,619.16. The trade was a 25.56 % decrease in their position. The disclosure for this sale can be found here. 3.90% of the stock is owned by corporate insiders.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.